Rotschafer J C, Shikuma L R
Drug Intell Clin Pharm. 1986 Jul-Aug;20(7-8):575-81. doi: 10.1177/106002808602000714.
Pseudomonas aeruginosa continues to be a leading cause of nosocomial bacteremia and other serious, often life-threatening infections. The incidence of P. aeruginosa infection appears to be increasing. The resilience of Pseudomonas in the hospital environment, its endogenous virulence factors, and its current level of resistance to antimicrobials make it a formidable pathogen, particularly in a compromised host. Despite the availability of several effective antipseudomonal antibiotics, infections caused by this pathogen are still associated with significant morbidity and mortality. Early recognition and prompt intervention with appropriate antimicrobial agents are vital to successful management. Combination therapy with an aminoglycoside and an extended-spectrum penicillin or cephalosporin is recommended in the initial management of suspected or documented P. aeruginosa infections.
铜绿假单胞菌仍然是医院获得性菌血症及其他严重的、常常危及生命的感染的主要病因。铜绿假单胞菌感染的发生率似乎在上升。该菌在医院环境中的顽强生存能力、其内在的毒力因子以及目前对抗菌药物的耐药水平使其成为一种可怕的病原体,尤其是在免疫功能低下的宿主中。尽管有几种有效的抗铜绿假单胞菌抗生素,但由该病原体引起的感染仍与显著的发病率和死亡率相关。早期识别并及时使用合适的抗菌药物进行干预对于成功治疗至关重要。在疑似或确诊的铜绿假单胞菌感染的初始治疗中,推荐使用氨基糖苷类药物与广谱青霉素或头孢菌素联合治疗。